Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Lantheus Holdings Inc (LNTH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: LNTH (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 139.78% | Avg. Invested days 42 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 6.60B USD | Price to earnings Ratio 22.05 | 1Y Target Price 134.38 |
Price to earnings Ratio 22.05 | 1Y Target Price 134.38 | ||
Volume (30-day avg) 978989 | Beta 0.38 | 52 Weeks Range 58.16 - 126.89 | Updated Date 03/30/2025 |
52 Weeks Range 58.16 - 126.89 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 4.36 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 20.37% | Operating Margin (TTM) 28.23% |
Management Effectiveness
Return on Assets (TTM) 15.35% | Return on Equity (TTM) 32.82% |
Valuation
Trailing PE 22.05 | Forward PE 13.4 | Enterprise Value 6304286896 | Price to Sales(TTM) 4.3 |
Enterprise Value 6304286896 | Price to Sales(TTM) 4.3 | ||
Enterprise Value to Revenue 4.11 | Enterprise Value to EBITDA 12.23 | Shares Outstanding 68611296 | Shares Floating 61796000 |
Shares Outstanding 68611296 | Shares Floating 61796000 | ||
Percent Insiders 2.75 | Percent Institutions 111.98 |
Analyst Ratings
Rating 4.62 | Target Price 134.69 | Buy 3 | Strong Buy 9 |
Buy 3 | Strong Buy 9 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Lantheus Holdings Inc
Company Overview
History and Background
Lantheus Holdings, Inc. was founded in 1956 as a division of DuPont. It was later spun off and has evolved into a leading provider of diagnostic and therapeutic products used in nuclear medicine and precision diagnostics.
Core Business Areas
- Precision Diagnostics: Provides diagnostic imaging agents for cardiology, neurology, and oncology to enable earlier and more accurate diagnoses.
- Strategic Therapeutic Applications: Focuses on radiotherapeutics for the treatment of various diseases, primarily oncology.
Leadership and Structure
Mary Anne Heino serves as the President and Chief Executive Officer. The company operates with a functional organizational structure with leadership across R&D, commercial operations, finance, and legal.
Top Products and Market Share
Key Offerings
- DEFINITY: An ultrasound contrast agent used in echocardiography. Competitors include GE Healthcare and Bracco Imaging. Revenue for DEFINITY contributes significantly to Lantheus' overall revenue, but specific market share data is dynamically driven by competition and formulary access.
- Pylotee: A PET imaging agent for prostate cancer. Early adoption in a growing market. Competitors include Blue Earth Diagnostics and Progenics Pharmaceuticals (now part of Lantheus). Market share is increasing as PET scans become more prevalent for prostate cancer detection and staging.
- TechneLite: A technetium generator used in nuclear medicine imaging. While a mature product, it remains a vital part of their portfolio. Market share is more stable due to its established role in routine imaging.
Market Dynamics
Industry Overview
The diagnostic imaging market is experiencing growth driven by advancements in technology, an aging population, and increasing prevalence of chronic diseases. The radiopharmaceutical market is expanding with new therapeutic applications in oncology.
Positioning
Lantheus is positioned as a leader in diagnostic imaging agents and a growing player in radiotherapeutics. Its competitive advantages include a diversified product portfolio and a strong distribution network.
Total Addressable Market (TAM)
The total addressable market for radiopharmaceuticals and diagnostic imaging agents is estimated to be in the tens of billions of dollars globally. Lantheus is strategically positioned to capture a significant share of this market, particularly with its Pylotee prostate cancer imaging agent.
Upturn SWOT Analysis
Strengths
- Established distribution network
- Diversified product portfolio
- Strong R&D capabilities
- Leadership in certain niche markets
Weaknesses
- Dependence on key products
- Exposure to regulatory changes
- Potential for generic competition
- Need for continued innovation
Opportunities
- Expansion into new therapeutic areas
- Strategic acquisitions and partnerships
- Increasing demand for precision diagnostics
- Growing adoption of radiotherapeutics
Threats
- Competition from larger pharmaceutical companies
- Pricing pressures
- Technological obsolescence
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- GE (GE)
- Siemens Healthineers (SIEGY)
- Bracco Imaging (Private)
Competitive Landscape
Lantheus competes with larger, more diversified companies in the diagnostic imaging and radiopharmaceutical markets. Its advantages include its specialized focus, innovative products, and strong customer relationships. Disadvantages are the smaller capital base.
Major Acquisitions
Progenics Pharmaceuticals (now Lantheus Medical Imaging)
- Year: 2019
- Acquisition Price (USD millions): 400
- Strategic Rationale: Enhanced pipeline and expanded capabilities in prostate cancer imaging and therapeutics.
Growth Trajectory and Initiatives
Historical Growth: Lantheus has experienced growth through product innovation, acquisitions, and expansion into new markets.
Future Projections: Future growth is projected based on continued adoption of its products, pipeline development, and strategic initiatives. Analyst estimates are available from various financial sources.
Recent Initiatives: Recent initiatives include the acquisition of Progenics Pharmaceuticals (now Lantheus Medical Imaging), expansion of manufacturing capabilities, and investment in R&D for new diagnostic and therapeutic agents.
Summary
Lantheus Holdings is a growing company in the diagnostic imaging and radiopharmaceutical market, with a strong product portfolio and strategic focus on precision diagnostics and radiotherapeutics. The company is making good initiatives in Prostate Cancer imaging and is expected to grow. Competition and regulatory changes are challenges to watch out for. Future acquisitions and the development of its pipeline will be the key to its success.
Similar Companies
- GE
- SIEGY
- MRK
Sources and Disclaimers
Data Sources:
- Lantheus Holdings Inc. Investor Relations
- SEC Filings (10-K, 10-Q)
- Market research reports
- Financial news sources
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Market conditions and company performance can change, impacting the accuracy of the analysis over time.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lantheus Holdings Inc
Exchange NASDAQ | Headquaters Bedford, MA, United States | ||
IPO Launch date 2015-06-25 | CEO & Director Mr. Brian A. Markison | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 808 | Website https://www.lantheus.com |
Full time employees 808 | Website https://www.lantheus.com | ||
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.